DexCom, Inc. (FRA:DC4)

Market Cap	24.34B -19.1%
Revenue (ttm)	4.18B +16.2%
Net Income	806.94M +73.8%
EPS	2.03 +75.5%
Shares Out	n/a
PE Ratio	30.16
Forward PE	27.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	62.60
Previous Close	63.20
Day's Range	62.60 - 62.60
52-Week Range	46.88 - 77.17
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 23, 2026

About DexCom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin;...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1999
• Employees: 11,050
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: DC4

Financial Performance

In 2025, DexCom's revenue was $4.66 billion, an increase of 15.60% compared to the previous year's $4.03 billion. Earnings were $836.30 million, an increase of 45.14%.

Financial numbers in USD